A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-17
DOI
10.1038/s41375-019-0573-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma
- (2018) Guillem Clot et al. BLOOD
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue
- (2018) S Ciavarella et al. ANNALS OF ONCOLOGY
- Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial
- (2018) Birte Friedrichs et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group
- (2017) Annette M. Staiger et al. JOURNAL OF CLINICAL ONCOLOGY
- New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
- (2017) David W. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Significance of stromal-1 and stromal-2 signatures and biologic prognostic model in diffuse large B-cell lymphoma
- (2017) Asmaa Gaber Abdou et al. Cancer Biology & Medicine
- Reference point insensitive molecular data analysis
- (2016) M. Altenbuchinger et al. BIOINFORMATICS
- Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
- (2015) David W. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma
- (2015) H Horn et al. LEUKEMIA
- Regularization Paths for Generalized Linear Models via Coordinate Descent
- (2015) Jerome Friedman et al. Journal of Statistical Software
- Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent
- (2015) Noah Simon et al. Journal of Statistical Software
- Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL
- (2014) N. Murawski et al. ANNALS OF ONCOLOGY
- Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
- (2014) D. W. Scott et al. BLOOD
- Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
- (2014) S. Riihijarvi et al. HAEMATOLOGICA
- High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma
- (2014) Francesco Marchesi et al. HEMATOLOGICAL ONCOLOGY
- Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group
- (2014) Michael Pfreundschuh et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma
- (2014) Gerhard Held et al. JOURNAL OF CLINICAL ONCOLOGY
- CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy
- (2013) Colm Keane et al. AMERICAN JOURNAL OF HEMATOLOGY
- Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens
- (2013) N. Masque-Soler et al. BLOOD
- MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
- (2013) H. Horn et al. BLOOD
- Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Nathalie A. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma
- (2012) David W. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
- (2012) Norbert Schmitz et al. LANCET ONCOLOGY
- Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
- (2011) G. Gutierrez-Garcia et al. BLOOD
- Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
- (2011) A. A. Alizadeh et al. BLOOD
- High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy
- (2011) T. M. Cardesa-Salzmann et al. HAEMATOLOGICA
- Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results
- (2011) Joshua Brody et al. JOURNAL OF CLINICAL ONCOLOGY
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
- (2011) Michael Pfreundschuh et al. LANCET ONCOLOGY
- High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma
- (2011) Qi-chun Cai et al. MEDICAL ONCOLOGY
- The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
- (2010) Paul N. Meyer et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
- (2010) G. Ott et al. BLOOD
- Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials
- (2008) W. Klapper et al. BLOOD
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
- (2008) W Klapper et al. LEUKEMIA
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now